% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schartmann:848233,
      author       = {Schartmann, Elena and Schemmert, Sarah and Niemietz, Nicole
                      and Honold, Dominik and Ziehm, Tamar and Tusche, Markus and
                      Elfgen, Anne and Gering, Ian and Brener, Oleksandr and Shah,
                      Nadim Joni and Langen, Karl-Josef and Kutzsche, Janine and
                      Willbold, Dieter and Willuweit, Antje},
      title        = {{I}n {V}itro {P}otency and {P}reclinical {P}harmacokinetic
                      {C}omparison of {A}ll-{D}-{E}nantiomeric {P}eptides
                      {D}eveloped for the {T}reatment of {A}lzheimer’s
                      {D}isease},
      journal      = {Journal of Alzheimer's disease},
      volume       = {64},
      number       = {3},
      issn         = {1387-2877},
      address      = {Amsterdam},
      publisher    = {IOS Press},
      reportid     = {FZJ-2018-03495},
      pages        = {859 - 873},
      year         = {2018},
      abstract     = {Diffusible amyloid-β (Aβ) oligomers are currently
                      presumed to be the most cytotoxic Aβ assembly and held
                      responsible to trigger the pathogenesis of Alzheimer’s
                      disease (AD). Thus, Aβ oligomers are a prominent target in
                      AD drug development. Previously, we reported on our solely
                      D-enantiomeric peptide D3 and its derivatives as AD drug
                      candidates. Here, we compare one of the most promising D3
                      derivatives, ANK6, with its tandem version (tANK6), and its
                      head-to-tail cyclized isoform (cANK6r). In vitro tests
                      investigating the D-peptides’ potencies to inhibit Aβ
                      aggregation, eliminate Aβ oligomers, and reduce Aβ-induced
                      cytotoxicity revealed that all three D-peptides efficiently
                      target Aβ. Subsequent preclinical pharmacokinetic studies
                      of the three all-D-peptides in wildtype mice showed
                      promising blood-brain barrier permeability with cANK6r
                      yielding the highest levels in brain. The peptides’
                      potencies to lower Aβ toxicity and their remarkable
                      brain/plasma ratios make them promising AD drug candidates.},
      cin          = {ICS-6 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)ICS-6-20110106 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {553 - Physical Basis of Diseases (POF3-553)},
      pid          = {G:(DE-HGF)POF3-553},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29966196},
      UT           = {WOS:000437257500014},
      doi          = {10.3233/JAD-180165},
      url          = {https://juser.fz-juelich.de/record/848233},
}